Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-861 for narcolepsy type 2
jRCT2031230050Completed
- Sponsor
- Takeda
- Start
- Jan 2023
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of oveporexton in narcolepsy type 2 (NT2) (3 arms), sponsored by Takeda. Primary endpoint: Change from baseline in average sleep latency on the Maintenance of Wakefulness Test at Week 8. Started Jan 2023; status: completed.
02
Drugs
oveporexton
03
Conditions
narcolepsy type 2 (NT2)
Beyond the preview
Go deeper on jRCT2031230050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230050.